![]() | |
Clinical data | |
---|---|
Other names | MRZ-8456 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C17H15BrN4O |
Molar mass | 371.238 g·mol−1 |
3D model ( JSmol) | |
| |
|
Remeglurant ( INN ; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu5 receptor. [1] [2] [3] It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016. [3]
![]() | |
Clinical data | |
---|---|
Other names | MRZ-8456 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C17H15BrN4O |
Molar mass | 371.238 g·mol−1 |
3D model ( JSmol) | |
| |
|
Remeglurant ( INN ; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu5 receptor. [1] [2] [3] It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016. [3]